Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Feb 29;10(1):15-25.
doi: 10.4244/AIJ-D-23-00010. eCollection 2024 Feb.

A 2024 scientific update on the clinical performance of drug-coated balloons

Florin-Leontin Lazar  1 , Horea-Laurentiu Onea  1 , Dan-Mircea Olinic  1 , Bernardo Cortese  2   3   4
Affiliations
Review

A 2024 scientific update on the clinical performance of drug-coated balloons

Florin-Leontin Lazar et al. AsiaIntervention. .

Abstract

Continuous advances in the field of interventional cardiology have led to the development of drug-coated balloons (DCB). These represent a promising device for overcoming the well-known limitations of traditional metallic stents, which are associated with a persistent yearly increased risk of adverse events. This technology has the ability to homogeneously transfer the drug into the vessel wall in the absence of a permanent prosthesis implanted in the coronary vessel. Robust data support the use of DCB for the treatment of in-stent restenosis, but there is also currently growing evidence from long-term follow-up of large randomised clinical trials regarding the use of these devices in other scenarios, such as de novo small and large vessel disease, complex bifurcations, and diffuse coronary disease. Other critical clinical settings such as diabetes mellitus, high bleeding risk patients and acute coronary syndromes could be approached in the upcoming future by using DCB, alone or as part of a blended strategy in combination with drug-eluting stents. There have been important scientific and technical advances in the DCB field in recent years. The purpose of this paper is to review the most current data regarding the use of DCB, including the mid- and long-term follow-up reports on the safety and efficacy of this novel strategy in different clinical and angiographic scenarios.

PubMed Disclaimer

Conflict of interest statement

The authors have no conflicts of interest to declare.

Figures

Figure 1
Figure 1. Three-year clinical outcomes of the PICCOLETO II trial.
DCB: drug-coated balloon; DES: drug-eluting stent; MACE: major adverse cardiac events; MI: myocardial infarction; TLR: target lesion revascularisation
Figure 2
Figure 2. EASTBOURNE Registry 12-month clinical follow-up.
MACE: major adverse cardiac events; MI: myocardial infarction; TLR: target lesion revascularisation
Central illustration
Central illustration. Potential benefits of drug-coated balloon use for coronary interventions.
CAD: coronary artery disease; DCB: drug-coated balloon; DES: drug-eluting stents; DM: diabetes mellitus; HBR: high bleeding risk; LLL: late lumen loss; MACE: major adverse cardiac events; MB: main branch; MI: myocardial infarction; POBA: plain old balloon angioplasty; SB: side branch; TLF: target lesion failure; TLR: target lesion revascularisation; TVF: target vessel failure; TVR: target vessel revascularisation; VT: vessel thrombosis
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Neumann FJ, Sousa-Uva M, Ahlsson A, Alfonso F, Banning AP, Benedetto U, Byrne RA, Collet JP, Falk V, Head SJ, Jüni P, Kastrati A, Koller A, Kristensen SD, Niebauer J, Richter DJ, Seferović PM, Sibbing D, Stefanini GG, Windecker S, Yadav R, Zembala MO. 2018 ESC/EACTS Guidelines on myocardial revascularization. EuroIntervention. 2019;14:1435–534. - PubMed
    1. von Birgelen, van der, Basalus MW, Kok MM, Sen H, Louwerenburg HW, van Houwelingen, Stoel MG, de Man, Linssen GC, Tandjung K, Doggen CJ, van der, Löwik MM. Five-Year Outcome After Implantation of Zotarolimus- and Everolimus-Eluting Stents in Randomized Trial Participants and Nonenrolled Eligible Patients. A Secondary Analysis of a Randomized Clinical Trial. JAMA Cardiol. 2017;2:268–76. - PubMed
    1. Fearon WF, Zimmermann FM, De Bruyne, Piroth Z, van Straten, Szekely L, Davidavičius G, Kalinauskas G, Mansour S, Kharbanda R, Östlund-Papadogeorgos N, Aminian A, Oldroyd KG, Al-Attar N, Jagic N, Dambrink JE, Kala P, Angerås O, MacCarthy P, Wendler O, Casselman F, Witt N, Mavromatis K, Miner SES, Sarma J, Engstrøm T, Christiansen EH, Tonino PAL, Reardon MJ, Lu D, Ding VY, Kobayashi Y, Hlatky MA, Mahaffey KW, Desai M, Woo YJ, Yeung AC, Pijls NHJ FAME 3 Investigators. Fractional Flow Reserve-Guided PCI as Compared with Coronary Bypass Surgery. N Engl J Med. 2022;386:128–37. - PubMed
    1. Ki YJ, Park KW, Kang J, Kim CH, Han JK, Yang HM, Kang HJ, Koo BK, Kim HS. Safety and Efficacy of Second-Generation Drug-Eluting Stents in Real-World Practice: Insights from the Multicenter Grand-DES Registry. J Interv Cardiol. 2020;2020:3872704. - PMC - PubMed
    1. Patel S, Svermova T, Burke-Gaffney A, Bogle RG. Drug-eluting balloons with provisional bail-out or adjunctive stenting in de novo coronary artery lesions-a systematic review and meta-analysis. Cardiovasc Diagn Ther. 2018;8:121–36. - PMC - PubMed